Loading clinical trials...
Loading clinical trials...
Intermediate-Size Patient Population Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
The purpose of this expanded access program (EAP) protocol is to provide investigational bezuclastinib to patients with a diagnosis of nonadvanced systemic mastocytosis (NonAdvSM) or advanced systemic mastocytosis (AdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Orso Health/Modena Asthma Allergy
La Jolla, California, United States
Scripps Green Hospital
La Jolla, California, United States
UCLA Ronald Reagan Medical Center
Los Angeles, California, United States
Sneeze Wheeze & Itch Associates LLC Clinical Research Center
Normal, Illinois, United States
Indiana University Health
Indianapolis, Indiana, United States
Walter Reed
Bethesda, Maryland, United States
AllerVie Health
Glenn Dale, Maryland, United States
Boston Specialists
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Michigan Medicine- University of Michigan
Ann Arbor, Michigan, United States
Last Updated
March 9, 2026
Bezuclastinib
DRUG
Lead Sponsor
Cogent Biosciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions